AU591466B2
(en)
*
|
1984-10-22 |
1989-12-07 |
Vestar, Inc. |
Method of delivering micellular particles encapsulating imaging and chemotherapeutic agents to tumors in a body
|
DE3510795C2
(de)
*
|
1985-03-25 |
1987-04-30 |
Udo Dr.med. 8400 Regensburg Ehrenfeld |
Verfahren zur Herstellung eines mikrobiellen Extrakts, das bei dem Verfahren erhaltene Produkt und ein es enthaltendes Arzneimittel
|
JPS62270531A
(ja)
*
|
1985-11-01 |
1987-11-24 |
サントル ナシヨナ−ル ド ラ ルシエルシユ シヤンテイフイ−ク(セ−・エン・エル・エス) |
生体内でのイメ−ジング及び治療用の新規エアロゾル組成物
|
JPS63107742A
(ja)
*
|
1986-05-20 |
1988-05-12 |
Wako Pure Chem Ind Ltd |
新規な機能性リポソ−ム及びその製造法
|
DE3621570A1
(de)
*
|
1986-06-27 |
1988-01-07 |
Hoechst Ag |
Diagnostikum zur szintigraphischen darstellung von boesartigen tumoren
|
EP0300102B1
(en)
*
|
1987-07-21 |
1993-03-24 |
The Stolle Research And Development Corporation |
Improved method of obtaining immune regulatory factors by mammal immunization
|
FR2644059B1
(fr)
*
|
1989-03-08 |
1994-03-04 |
Fabre Medicament Pierre |
Compositions aerosols destinees a l'imagerie, au diagnostic et a la therapie ciblee de foyers inflammatoires et tumoraux
|
FR2655546B1
(fr)
*
|
1989-12-11 |
1992-03-13 |
Assistance Publique |
Composition pour injection intratumorale, et utilisation pour le marquage prechimiotherapique et preoperatoire, en laserotherapie et en thermotherapie.
|
US5620703A
(en)
*
|
1991-10-11 |
1997-04-15 |
Max-Delbruck-Centrum Fur Molekulare Medizin |
Stimulating hematopoietic activity with carboplatin or lobaplatin
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US6649143B1
(en)
|
1994-07-01 |
2003-11-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US5650135A
(en)
*
|
1994-07-01 |
1997-07-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US7255851B2
(en)
|
1994-07-01 |
2007-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
EP1820517A3
(en)
*
|
1995-11-17 |
2009-10-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
CN1539970A
(zh)
|
1996-10-25 |
2004-10-27 |
�Ϻ���ͨ��ѧ |
嗜中性白细胞因子α
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
WO1999047677A2
(en)
|
1998-03-17 |
1999-09-23 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
EP2332975A1
(en)
|
1997-05-30 |
2011-06-15 |
Human Genome Sciences, Inc. |
Human proteins
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
CN1253551C
(zh)
*
|
1997-09-10 |
2006-04-26 |
维昂药品公司 |
减毒的遗传修饰肿瘤靶向细菌
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
CA2318857C
(en)
|
1998-02-04 |
2013-09-24 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
JP2002506625A
(ja)
|
1998-03-19 |
2002-03-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
サイトカインレセプター共通γ鎖様
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2001077137A1
(en)
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US6962696B1
(en)
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2168980A1
(en)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
WO2003018754A2
(en)
|
2001-08-24 |
2003-03-06 |
Neuronz Limited |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
US7060278B2
(en)
|
2001-08-29 |
2006-06-13 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
CA2461345A1
(en)
|
2001-09-24 |
2003-04-03 |
Imperial College Innovations Ltd. |
Use of pyy or agonist thereof to modify feeding behaviour
|
EP1439857B1
(en)
|
2001-10-12 |
2009-02-25 |
Schering Corporation |
USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
JP4733922B2
(ja)
|
2002-01-10 |
2011-07-27 |
インペリアル・イノベ−ションズ・リミテッド |
摂食行動の修正
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2508375C
(en)
|
2002-12-02 |
2014-05-27 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
MXPA05009743A
(es)
|
2003-03-12 |
2006-03-09 |
Genentech Inc |
Composiciones con actividad hematopoyetica e inmune.
|
CA2519528C
(en)
|
2003-03-19 |
2016-01-26 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
EP2457586A1
(en)
|
2003-06-27 |
2012-05-30 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
ATE536186T1
(de)
|
2003-09-12 |
2011-12-15 |
Tercica Inc |
Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
|
MXPA06008506A
(es)
|
2004-02-02 |
2007-01-30 |
Ambrx Inc |
Polipeptidos de hormona de crecimiento humana modificada y sus usos.
|
WO2005090564A1
(ja)
|
2004-03-19 |
2005-09-29 |
Genomidea Inc. |
血管内皮増殖促進遺伝子
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
AU2005265163B2
(en)
*
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
AU2005327906B2
(en)
*
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
WO2006037182A1
(en)
|
2004-10-06 |
2006-04-13 |
Agri-Biotech Pty Ltd |
Antibody production method
|
AU2005307831A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen, Inc. |
Fully human monoclonal antibodies to IL-13
|
EP1838737B1
(en)
|
2004-12-20 |
2011-04-06 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
EP1836298B1
(en)
*
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
NZ555206A
(en)
*
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
JP5425398B2
(ja)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
JP2008541769A
(ja)
*
|
2005-06-03 |
2008-11-27 |
アンブレツクス・インコーポレイテツド |
改善されたヒトインターフェロン分子及びそれらの使用
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
PT1899378E
(pt)
|
2005-06-21 |
2010-01-26 |
Xoma Technology Ltd |
Anticorpos de ligação de il-1β e os seus fragmentos
|
NZ565953A
(en)
|
2005-07-27 |
2012-01-12 |
Univ Florida |
Small compounds that correct protein misfolding and uses thereof
|
ES2408581T3
(es)
*
|
2005-08-18 |
2013-06-21 |
Ambrx, Inc. |
Composiciones de ARNt y usos de las mismas
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
RS51998B
(en)
*
|
2005-11-08 |
2012-04-30 |
Ambrx Inc. |
ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
|
AU2006315580A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
|
EP1951890A4
(en)
*
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
CA2633956C
(en)
|
2005-12-13 |
2016-12-06 |
Olivia Raeber |
Binding proteins specific for insulin-like growth factors and uses thereof
|
CN101448512B
(zh)
*
|
2005-12-14 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
EP1969003B8
(en)
|
2005-12-14 |
2010-11-10 |
Hermo Pharma Ltd. |
Uses of a NEUROTROPHIC FACTOR PROTEIN
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
KR101067525B1
(ko)
|
2005-12-22 |
2011-09-27 |
제넨테크, 인크. |
헤파린 결합 단백질의 재조합 생산
|
US20070190127A1
(en)
|
2005-12-30 |
2007-08-16 |
Mingdong Zhou |
Extended release of neuregulin for improved cardiac function
|
JP4923625B2
(ja)
*
|
2006-03-01 |
2012-04-25 |
パナソニック株式会社 |
炊飯器
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2049570B1
(en)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
EP2054437A2
(en)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
ES2457527T3
(es)
*
|
2006-09-08 |
2014-04-28 |
Ambrx, Inc. |
ARNt Supresor hibrido en células de vertebrados
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
SG174788A1
(en)
*
|
2006-09-08 |
2011-10-28 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
CA2673592C
(en)
|
2006-12-20 |
2014-03-25 |
Xoma Technology Ltd. |
Methods for the treatment of il-1.beta. related diseases
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
CA2685596A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
US20110065673A1
(en)
|
2007-05-11 |
2011-03-17 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor agonist
|
MX2009013765A
(es)
|
2007-06-27 |
2010-02-01 |
Auckland Uniservices Ltd |
Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
SI2207809T1
(sl)
|
2007-09-26 |
2013-11-29 |
U3 Pharma Gmbh |
Proteini, ki veĹľejo antigen rastnega faktorja, podobnega epidermalnemu rastnemu faktorju, ki veĹľe heparin
|
KR101656107B1
(ko)
*
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
EP2391650B1
(en)
|
2007-12-20 |
2014-10-15 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
EP2684873B1
(en)
|
2008-06-09 |
2019-01-16 |
Ludwig-Maximilians-Universität München |
Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
MX2011000859A
(es)
*
|
2008-07-23 |
2011-02-24 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados y sus usos.
|
EP2316030B1
(en)
|
2008-07-25 |
2019-08-21 |
Wagner, Richard W. |
Protein screeing methods
|
SG193209A1
(en)
|
2008-09-10 |
2013-09-30 |
Genentech Inc |
Methods for inhibiting ocular angiogenesis
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
TR201802361T4
(tr)
|
2008-09-26 |
2018-03-21 |
Ambrx Inc |
Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
|
MX346001B
(es)
|
2008-09-26 |
2017-03-01 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
EP2390261A4
(en)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
WO2010092109A2
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
US8283162B2
(en)
*
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(da)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
US20120282266A1
(en)
|
2009-10-16 |
2012-11-08 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
US8623416B2
(en)
|
2009-11-25 |
2014-01-07 |
Michael Zasloff |
Formulations comprising aminosterols
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
BR112012015461A2
(pt)
|
2009-12-21 |
2017-01-10 |
Ambrx Inc |
polipeptídeos de somatotropina boviina modificados e seus usos
|
EP2525792A1
(en)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
AU2011210825B2
(en)
|
2010-01-27 |
2017-02-02 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
EP2561068A1
(en)
|
2010-04-19 |
2013-02-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
US9320756B2
(en)
|
2010-05-07 |
2016-04-26 |
Centre National De La Recherche Scientifique |
UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
|
JP5709985B2
(ja)
|
2010-06-18 |
2015-04-30 |
シーバーサイエンス ゲーエムベーハー |
生体バリアを安定化させる活性剤としてのペプチド
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MY162837A
(en)
|
2010-08-17 |
2017-07-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CA2823218C
(en)
|
2011-01-27 |
2021-04-20 |
Neuren Pharmaceuticals Limited |
Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
|
AU2012225248A1
(en)
|
2011-03-10 |
2013-09-19 |
Genentech, Inc. |
Treatment of disorders with altered vascular barrier function
|
EA032666B1
(ru)
|
2011-06-14 |
2019-06-28 |
Бикам Фармасьютикалз, Инк. |
Опсинсвязывающие лиганды и способы их применения
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
EP2745113B1
(en)
|
2011-08-16 |
2017-03-22 |
Evotec (München) GmbH |
Markers for susceptibility to an inhibitor of an src-family kinase
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
EP2780040A1
(en)
|
2011-11-16 |
2014-09-24 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
US9944685B2
(en)
|
2012-07-02 |
2018-04-17 |
Medizinische Universität Wien |
Complement split product C4d for the treatment of inflammatory conditions
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
AU2013305888A1
(en)
|
2012-08-21 |
2015-02-26 |
Genesys Research Institute |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
EP2999797B1
(en)
|
2013-05-21 |
2018-07-04 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
AU2014270882B2
(en)
|
2013-05-22 |
2019-03-14 |
Zensun (Shanghai) Science & Technology, Co. Ltd. |
Extended release of neuregulin for treating heart failure
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
AU2014318579A1
(en)
|
2013-09-13 |
2016-04-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
EP3494985B1
(en)
|
2013-09-16 |
2021-02-24 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Vaccine composition comprising mutant calreticulin
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
CA2926698C
(en)
|
2013-10-15 |
2021-06-22 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
CN106456589B
(zh)
|
2013-12-18 |
2020-07-07 |
斯克利普斯研究所 |
修饰的治疗剂、订合的肽脂质缀合物及其组合物
|
WO2015121457A1
(en)
|
2014-02-13 |
2015-08-20 |
Westphal Sören |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
EP3183346A4
(en)
|
2014-08-22 |
2018-10-24 |
Auckland Uniservices Limited |
Channel modulators
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
CN107108710B
(zh)
|
2014-10-24 |
2022-02-15 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
US20190000928A1
(en)
|
2015-06-17 |
2019-01-03 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
CN108834415B
(zh)
|
2015-11-13 |
2021-12-24 |
多曼治疗学公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
|
WO2017097986A1
(en)
|
2015-12-09 |
2017-06-15 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
US20190100549A1
(en)
|
2016-01-15 |
2019-04-04 |
Universitaet Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
JP2019508496A
(ja)
|
2016-02-15 |
2019-03-28 |
チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療法のためのtaf1阻害剤
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
US20190111069A1
(en)
|
2016-04-15 |
2019-04-18 |
Oxford University Innovation Limited |
Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
JP7149935B2
(ja)
|
2016-10-19 |
2022-10-07 |
ザ スクリプス リサーチ インスティテュート |
ヒト化された標的化部分および/または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
|
MX2019005443A
(es)
|
2016-11-14 |
2019-11-21 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
|
AU2017368286B2
(en)
|
2016-11-30 |
2021-12-16 |
Medizinische Universität Innsbruck |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
WO2018206820A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
US11180518B2
(en)
|
2017-05-12 |
2021-11-23 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
MODULATION OF CYTOKINE
|
EP3704132A4
(en)
|
2017-10-30 |
2021-07-28 |
Enterin, Inc. |
NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
|
FR3072880A1
(fr)
*
|
2017-10-30 |
2019-05-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Formulation liposomale et son utilisation en therapie anti-tumorale
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
CA3096146A1
(en)
|
2018-04-06 |
2019-10-10 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
JP2021535140A
(ja)
|
2018-08-28 |
2021-12-16 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
抗cd3抗体葉酸生物複合体およびその使用
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
US20220009986A1
(en)
|
2018-10-19 |
2022-01-13 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
WO2020127200A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
CA3128081A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
AU2020323901A1
(en)
|
2019-07-26 |
2022-02-24 |
Amgen Inc. |
Anti-IL13 antigen binding proteins
|
JP2022544549A
(ja)
|
2019-08-12 |
2022-10-19 |
ピュリノミア バイオテック, インコーポレイテッド |
Cd39発現細胞のadcc標的化を介してt細胞媒介性免疫応答を促進及び増強するための方法及び組成物
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
US20230064948A1
(en)
|
2019-10-02 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
AU2020366135A1
(en)
|
2019-10-16 |
2022-06-02 |
Proxygen Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021081440A2
(en)
|
2019-10-24 |
2021-04-29 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
IL292919A
(en)
|
2019-11-19 |
2022-07-01 |
Modag Gmbh |
New compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
EP4171562A1
(en)
|
2020-06-25 |
2023-05-03 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022079290A2
(en)
|
2020-10-16 |
2022-04-21 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Cullin ring ubiquitin ligase compounds and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
BR112023020538A2
(pt)
|
2021-04-07 |
2024-01-23 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
WO2022241465A1
(en)
|
2021-05-14 |
2022-11-17 |
Claris Biotherapeutics, Inc. |
Compositions of growth factor for the treatment of eye disease
|
WO2023203378A1
(en)
|
2022-04-19 |
2023-10-26 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|